STOCK TITAN

NeOnc Technologies Holdings (NTHI) Stock News, Oct-Nov 2026

NTHI NASDAQ

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.

Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.

Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.

By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) will present data from its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting on November 13, 2026.

The two posters cover intranasal NEO100 in recurrent IDH1-mutant astrocytoma, including updated Phase 1/2a and compassionate-use experience, and oral NEO212 in treatment-resistant recurrent glioblastoma and brain metastases. The NEO212 presentation addresses Phase 1 safety, drug behavior in the body and early activity signals. Both presentations are scheduled for 7:30 to 9:30 p.m. EST at the Pennsylvania Convention Center in Philadelphia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (NASDAQ:NTHI) outlined plans for a pivotal brain cancer trial targeting approximately 500 patients internationally. The proposed study would span 30 hospitals in three countries and investigate NEO100, its investigational brain cancer treatment. A December 2025 update described radiographic remission in six of 25 patients, approximately 24%, across combined clinical and compassionate-use experience; these observations remain preliminary.

Separately, NEO212 completed Phase 1 dose-escalation work. An FDA meeting scheduled for November 17 will discuss potential Phase 2 development, including study design, patient population, dosing and endpoints. October 15 Nasdaq market data showed approximately 877,000 shares short, representing approximately 5.6 days of trading volume at the ten-day average.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) outlined plans for an international brain cancer trial targeting approximately 500 patients across three countries. The proposed study envisions around 30 hospitals; these targets are not completed enrollment.

The investigational NEO100 program uses administration through the nose, designed to bypass the blood-brain barrier that can prevent therapies from reaching brain tumors. A December 2025 clinical update reported significant radiographic remission in six of 25 patients across combined clinical and compassionate-use experience. These preliminary observations came from a small, nonrandomized population and do not establish effectiveness or predict individual outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.76%
Tags
none
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) moved above $3 as clinical developments and an Abu Dhabi research memorandum accompanied the stock's reported breakout. The price move and trading-volume characterization require verification against live data; some technical figures are historical references.

An October 21 memorandum with the Department of Health–Abu Dhabi covers proposed scientific exchange, training and potential research. Two children were receiving investigational NEO100 through Compassionate Care, with a third expected. NeOnc reported physicians observed independent breathing and emerging leg movement in a treated three-year-old boy. An FDA meeting is scheduled for November 17. Reported short interest rose approximately 45.1% from September 15 to September 30. Published analyst targets range from $13 to $20.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.85%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) is scheduled to discuss its brain cancer research on Fox Business Network on October 25.

CEO Amir F. Heshmatpour and founder and Chief Scientific Officer Thomas Chen will appear on Health Uncensored with Dr. Drew at 5:30 p.m. ET. NeOnc has announced a memorandum of understanding with Abu Dhabi’s Department of Health to explore research collaboration, training and possible future clinical studies. Separately, treating physicians reported that a three-year-old boy receiving investigational NEO100 through its Compassionate Care program in Abu Dhabi was breathing without ventilator support and beginning to move his legs after treatment began.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) will appear on Health Uncensored with Dr. Drew on October 25, 2026, to discuss investigational brain-tumor treatment.

The segment is scheduled for 5:30 p.m. ET / 2:30 p.m. PT on Fox Business Network, with timing subject to change. Executives Amir F. Heshmatpour and Thomas Chen will discuss NEO100, an investigational therapy administered through the nose and in clinical development in adults and children. Its delivery approach is designed to provide a non-invasive route to the brain; safety and efficacy have not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) signed a research collaboration memorandum with the Department of Health – Abu Dhabi covering oncology and central nervous system therapeutics. The nonbinding, two-year framework covers scientific exchange, training and clinical development; research and regional operations require separate agreements and applicable approvals.

Two children are receiving investigational NEO100 through compassionate care, with a third expected this week. NeOnc is working to open a Phase 1 study in Abu Dhabi, with additional requirements pending before enrollment. Its previously reported 24-patient, open-label Phase 2a study met its primary endpoint: six-month progression-free survival was 48.9%, versus a pre-specified 20% benchmark.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (Nasdaq: NTHI) signed a non-binding memorandum of understanding with the Department of Health – Abu Dhabi for CNS oncology collaboration. The two-year framework covers scientific exchange, specialist training and real-world evidence, with proposed clinical research and a potential regional presence.

Two children in Abu Dhabi are receiving investigational NEO100 through compassionate care; NeOnc expects a third child from India this week. The company is working to open a Phase 1 NEO100 study in the Emirate. June 2026 research clearances covered NEO100 and NEO212, but UAE enrollment requires additional conditions, including separate institutional review board approval. Pediatric NEO100 studies remain subject to further protocol review. Clinical collaboration and potential manufacturing, supply or distribution activities require separate agreements and applicable approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
Rhea-AI Summary

NeOnc Technologies Holdings (NASDAQ:NTHI) has scheduled an FDA End-of-Phase 1 meeting for November 17, 2026, to discuss investigational NEO212. Topics include the proposed Phase 2 population, design, endpoints, dose and evidence for a future marketing application. Dose escalation is complete, with 610 mg selected for Phase 2 after a dose-limiting toxicity at 810 mg.

On October 16, NeOnc reported physicians observed early improvement in a three-year-old receiving investigational NEO100 through compassionate use in Abu Dhabi, including independent breathing and leg movement. The company cautioned that this case does not establish causation or predict other patients’ outcomes. Abu Dhabi’s Department of Health granted investigational authorization in June for adult NEO100 development and a pediatric pathway subject to further protocol review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) reported early improvement in a critically ill child receiving investigational NEO100 through its Compassionate Care program. The three-year-old is breathing without ventilator support and beginning to move his legs. Treatment is outside the pediatric trial; this single case cannot establish that NEO100 caused the improvement.

A 24-patient Phase 2a study reported 48.9% six-month progression-free survival and median overall survival of 26.09 months. NeOnc completed a $15 million registered direct offering and announced redemption of its Series A convertible preferred stock. NEO212 completed Phase 1 dose escalation; a November 17 FDA meeting is scheduled to discuss potential Phase 2 development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none

FAQ

What is the current stock price of NeOnc Technologies Holdings (NTHI)?

NeOnc Technologies Holdings (NTHI) last closed at $4.54.

What is the market cap of NeOnc Technologies Holdings (NTHI)?

The market cap of NeOnc Technologies Holdings (NTHI) is approximately $131.0M.